文献速递膀胱癌与上尿路尿路上皮癌

癌症基因组图谱表达亚型可分层晚期尿路上皮癌对检查点抑制的应答并识别高生存概率患者亚群

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.
PubMed 文献 · Eur Urol · 2019-03-07

基于IMvigor 210试验中铂难治或不适合顺铂的尿路上皮癌患者接受阿替利珠单抗治疗的数据,对368份肿瘤样本进行转录组分析,发现「基因组不稳定」Lund亚型与最佳应答相关;基于癌症基因组图谱2017表达分子亚型开发单患者分类器,识别出11例神经元亚型患者,8例确认应答者应答率100%,总应答率72%(含3/11未确认应答),该亚型生存概率极高。

要点

  • 基于癌症基因组图谱2017表达分子亚型的单患者分类器可对个体肿瘤进行基因组分类。
  • 神经元亚型11例中8例确认应答者应答率100%(2例完全缓解,6例部分缓解),含未确认应答总应答率72%。
  • 神经元亚型代表晚期高危队列但生存概率极高,可能继发于低TGFβ表达和高突变/新抗原负荷。

核心结论

  • 基于癌症基因组图谱2017表达分子亚型的单患者分类器识别出的神经元亚型与免疫治疗高应答率相关,且该亚型生存概率极高。

研究设计与样本

  • 分析IMvigor 210试验中铂难治或不适合顺铂的尿路上皮癌患者接受PD-L1抑制剂阿替利珠单抗治疗的数据,对368份肿瘤样本进行转录组分析。
  • 开发并应用基于癌症基因组图谱2017表达分子亚型的单患者亚型分类器。

主要发现

  • 「基因组不稳定」Lund亚型分类与最佳应答相关。
  • 识别出11例神经元亚型患者,8例确认应答者应答率100%(2例完全缓解,6例部分缓解),含3/11未确认应答的总应答率72%。
  • 神经元亚型生存概率极高,该亚型代表晚期高危队列,可能继发于低TGFβ表达和高突变/新抗原负荷。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Analysis of the IMvigor 210 trials involving patients with platinum-refractory or cisplatin-ineligible urothelial carcinoma who were treated with the PD-L1 inhibitor atezolizumab identified a resistance signature as an immune biomarker. Transcriptome profiling of 368 tumor samples from this trial revealed that the "genomically unstable" Lund subtype classification was associated with the best response. We developed and applied a novel single-patient subtype classifier based on The Cancer Genome Atlas 2017 expression-based molecular subtypes. We identified 11 patients with a neuronal subtype, with a 100% response rate in eight confirmed cases (2 complete response, 6 partial response), and 72% overall, including 3/11 patients with an unconfirmed response. The survival probability was extraordinarily high for the neuronal subtype, which represents a high-risk cohort with advanced disease, and may be secondary to low levels of TGFβ expression and high mutation/neoantigen burden. PATIENT SUMMARY: We describe a methodology for genomic classification of an individual patient's bladder cancer tumor and have identified a subtype that is associated with a high response rate to immunotherapy. This is an important step forward in identifying the right treatment for the right patient, which is the goal of personalized precision medicine.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Kim J, Kwiatkowski D, McConkey DJ, et al. The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. Eur Urol. 2019. PMID: 30851984. doi:10.1016/j.eururo.2019.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。